Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
P/E ratio for Neuronetics, Inc. (STIM)
P/E ratio as of 2023: -2.75
According to Neuronetics, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -2.75. At the end of 2022 the company had a P/E ratio of -4.71.
P/E ratio history for Neuronetics, Inc. from 2016 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -2.75 |
| 2022 | -4.71 |
| 2021 | -3.19 |
| 2020 | -6.48 |
| 2019 | -2.41 |
| 2018 | -7.19 |
| 2017 | -0.02 |
| 2016 | -0.03 |